Medical network on December 21 - global bristol-myers squibb pharmaceutical giant Merck Germany and the United States in the global sales of single drug patent love will be completed (common name, cetuximab) 2017 patents expire, is causing domestic drug firms compete to imitation.
Foshan AnPuZe biological pharmaceutical co., LTD. Has officially announced its first project (cetuximab injection), the approval documents for clinical embarks on cetuximab issue of clinical trials, and high-profile joint aj securities issued new three board plan together.
State food drug safety administration according to the latest figures, there are 7 enterprises obtain the clinical approval of cetuximab. Have analysis refers to the fact that in 2015 China monoclonal antibody drug resistance (single) sales of 7 billion yuan, although in the past five years the compound growth rate of 34.4%, but the current of resistance to drugs accounted for only 9.7%. With the increase of patent medicine expires and the domestic research and development strength, the future will is expected to more than 30 billion market size of the sprint.
Seven drug firms to generic business
As a star in the field of anti-tumor drug, love will be completed in 1997, has been listed in the United States, and the 2015 global sales of $1.996 billion. However, the drug is entrusted repackaging in domestic sales in 2004.
"Due to the drug import prices are too high, 60000 to 80000 yuan, a period of treatment to the whole course of down to hundreds of thousands of high fees are cracking down on domestic demand. The drug is currently only in Tibet into the health care, in China only 300 million yuan." AnPuZe biological medicine, general manager of Liang Huiqing told SMW reporter.
According to its AnPuZe, now will cetuximab pharmaceutical r&d project listed as one of strategic research and development projects, is expected in the next four years, will complete all the clinical trials.
Actually present in the imitation of love will be completed in fact more than a AnPuZe, Charley roadshow expert introduction, according to financing in order to compete for love with patents expire market cake, there are qilu AnPuZe, guilin sanjin pharmaceutical, foshan, Shanghai citic health pharmaceutical co., Shanghai forte macro han graduated from biological koren pharmaceutical, Harbin pharmaceutical group, sichuan and other seven drug firms got the clinical entity.
Single generic drug resistance or promote high drug prices
For many domestic pharmaceutical companies rob package insert drug resistance, the analysis thinks, global biological medicine overall is still in its infancy, the domestic start although late, but has the potential to catch up with, for domestic biological pharmaceutical companies, is a great opportunity.
Because in accordance with the "guild regulations", a third of the generic drug prices usually is patent medicine. Once the product, price will be significantly lower than similar imported drugs, at the same time enjoy the import brand medicine has to develop the market, will achieve amazing sales revenue.
Resistance to yasuhiro miyata pharmaceutical's single blockbuster "compaq heap eye ophthalmic injection" as an example, the drug after successful research and development, the impressive performance in these two years by the industry. Yasuhiro miyata pharmaceutical half annual report, 2016 just two years of compaq heap, net sales of the first six months of the year is 220 million yuan, up 109% from a year earlier. The 10% and the pharmaceutical industry in China the status quo in contrast to the sluggish growth.
Compaq heap listed also reversed transmission in the field of the world's first brand licensed imported drugs, the patent in China is far from maturity, active, prices nearly 27%.
According to Charley, single resistance to markets around the world show explosive growth, from $2000 in 3.2 billion, the growth of 15 to 20 years of $98 billion, compound annual growth rate of 25. 76% and is expected to single resistance to sales will reach $2020 in 220 billion. In addition, the single resistance in the market position in the fields of biological products has also from 2. In 1997 to 5% in 2015, 34. 7%, at present, as the world's biological products industry in the market of the biggest industry.
Cic advisory forecasting means, by 2020, an industry in China market scale will reach $28 billion, 2016-2020 average annual compound growth rate of 30%.
The relevant data
Love will be completed is targeted drugs for the treatment of colorectal cancer
Love will be completed in China sales (cetuximab injection) by the German Merck registered in China, mainly used in the treatment of metastatic colorectal cancer. In the first-line treatment of metastatic colorectal cancer, love will be completed to the xsl-fo LFO X reached so far reported the highest response rate (81%) in the clinical treatment effect is remarkable. Compared with traditional chemotherapy drugs, love will be completed this type of molecular targeted therapy drugs like creatures precision-guided missiles, precision tumor cells with little injury and normal cells, on the action mechanism different from traditional chemotherapy drugs, no serious side effects. |
